Who manufactures Attruby (Acoramidis)?

Acoramidis bulk supplier for pharma manufacturers

Acoramidis Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 356 mg (as 400 mg acoramidis hydrochloride)

Reference Brands: Attruby (US); Beyonttra (EU, UK, Japan)

Acoramidis is a first-in-class oral transthyretin (TTR) stabilizer designed for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. This rare and progressive heart condition can lead to heart failure and increased risk of cardiovascular death. Acoramidis works by stabilizing the TTR protein, preventing amyloid deposits in the heart, thereby reducing cardiovascular death and related hospitalizations.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Acoramidis? List it or send an offer →

Product Description:

Acoramidis is an oral transthyretin stabiliser. Transthyretin is a four-part protein that carries thyroxine and vitamin A; when it falls apart, the pieces misfold and deposit as amyloid in the heart, causing transthyretin amyloid cardiomyopathy. Acoramidis binds the protein and holds it together, mimicking a naturally occurring genetic variant that protects carriers from the disease. It achieves near-complete stabilisation, above 90%, which is the basis of its marketing position against the earlier stabiliser tafamidis.

In its pivotal trial it reduced a composite of death and cardiovascular hospitalisation over thirty months in patients with the wild-type or hereditary disease. It is taken twice daily with food. It is generally well tolerated; diarrhoea and upper abdominal pain are the most reported effects. Diagnosis requires bone scintigraphy or biopsy plus exclusion of light-chain amyloidosis, so the destination market needs that diagnostic pathway.

Sourcing notes. Originator product, on patent, with no generic. Approved in the US in 2024 and in the EU, UK and Brazil since, with different companies commercialising it inside and outside the US. Annual cost is high and access usually runs through specialist amyloidosis centres. Treat enquiries as authorised-distribution or named-patient supply.

How Acoramidis is supplied today, and licensing ahead of patent expiry

Acoramidis is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Acoramidis, hold a dossier for it or want to license it, talk to us.

Where acoramidis is approved

Checked 3 Oct 2026

Market	Status	Brand · regulator · date
United States	Approved	Attruby · FDA · Nov 2024
European Union	Approved	Beyonttra · European Commission · Feb 2025
Japan	Approved	Beyonttra · MHLW · Mar 2025
Generic / biosimilar	None	None approved as of the check date

Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Acoramidis supply →

Back to Listing

Frequently Asked Questions

Acoramidis is sold as Attruby and Beyonttra. It is developed and sold by BridgeBio (Bayer markets Beyonttra in Europe). PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.